Trials / Withdrawn
WithdrawnNCT01018225
Exploratory Study Evaluating the Effects of Darifenacin on Nocturia, Sleep and Daytime Wakefulness
- Status
- Withdrawn
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Cognitive Research Corporation · Industry
- Sex
- All
- Age
- 21 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy of darifenacin in the treatment of moderate to severe nocturia in patients with overactive bladder and who do not have non-urologic causes of nocturia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | darifenacin | 7.5 or 15 mg darifenacin, once a day for 6 weeks |
| DRUG | Placebo | Placebo pill, once a day, for six weeks |
Timeline
- Start date
- 2009-11-01
- Completion
- 2010-07-01
- First posted
- 2009-11-23
- Last updated
- 2016-04-13
Source: ClinicalTrials.gov record NCT01018225. Inclusion in this directory is not an endorsement.